Analysis of the predictive efficacy of pleural fluid CEA, serum CEA, and pleural fluid CEA/serum CEA combined with pleural fluid CEA for EGFR mutations in lung adenocarcinoma patients with MPE. This evidence concerns the gene EGFR and lung adenocarcinoma.